Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + mifepristone
- Development stage
- Phase 1
- Lead developer
- Nova Southeastern University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This investigational sequential combination therapy is being developed by Nova Southeastern University's Institute for Neuro-Immune Medicine to treat Gulf War Illness (GWI). The treatment protocol is designed to 'reset' dysregulated homeostatic networks by first administering etanercept, a biologic TNF-alpha inhibitor, to reduce systemic inflammation, followed by mifepristone, a small molecule glucocorticoid receptor antagonist. The strategy aims to break the cycle of chronic neuro-immune dysfunction by lowering inflammatory signaling and then temporarily blocking stress hormone receptors to normalize the hypothalamic-pituitary-adrenal (HPA) axis. It is currently being evaluated in Phase I clinical trials specifically for male veterans with GWI.
- Other names
- Etanercept and Mifepristone for Gulf War IllnessSequential etanercept-mifepristone interventionTNF and Glucocorticoid Antagonist for Gulf War Illness-Associated Multi-symptom Disease Homeostasis Reset
02
Targets
GR (Glucocorticoid receptor)PR (Progesterone receptor)TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on etanercept + mifepristone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + mifepristone.